Charlie Bolten was recruited to BioGenerator in July of 2009. At the time of his recruitment to BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology collaboration with PTC Therapeutics focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor. Prior to Pfizer, Charlie worked on pharma project teams in various therapeutic areas at Pharmacia and Searle. Charlie began his career in agricultural research at Monsanto. Example BioGenerator portfolio companies for Charlie include Adarza BioSystems, Canopy BioSciences, Tioma Therapeutics, Medibeacon, Confluence Discovery Technologies, Arvegenix, Euclises Pharmaceuticals, Viba Therapeutics, SynerZ Medical, and Indalo Therapeutics. In addition to investments and company creation, Charlie has oversight over the BioGenerator Labs, Entrepreneur in Residence Program, BioSTL Fundamentals, Grants2Business, i6 Proof of Concept Center, and is a member of the BioGenerator leadership team.